SKYE · Skye Bioscience, Inc.
$0.61
-0.01 (-1.45%)
At close · Jul 29
Going-concern doubt
— flagged May 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions give rise to substantial doubt as to the Company's ability to continue as a going concern within one year after the date that these financial statements are issued. After considering the plans to alleviate substantial doubt, management has concluded that there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that these financial statements are issued.”View the 10-Q filed May 11, 2026
Market Cap
$21.61M
Shares
35.14M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Punit Dhillon | CEO | $1,361,831 |
| Kaitlyn Arsenault | CFO | $888,589 |
| Tu Diep | COO | $875,939 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Punit Dhillon | CEO | $6,139,625 |
| Kaitlyn Arsenault | CFO | $2,266,825 |
| Tu Diep | COO | $2,207,168 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Punit Dhillon | CEO | $1,807,338 |
| Kaitlyn Arsenault | CFO | $1,270,290 |
| Tu Diep | COO | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| John P. Sharp | Chief Financial Officer | Appointed | 2026-04-03 |
| Punit Dhillon | principal accounting officer | Appointed | 2026-02-20 |